122 related articles for article (PubMed ID: 14678984)
1. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography.
Krix M; Kiessling F; Vosseler S; Farhan N; Mueller MM; Bohlen P; Fusenig NE; Delorme S
Cancer Res; 2003 Dec; 63(23):8264-70. PubMed ID: 14678984
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S
Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333
[TBL] [Abstract][Full Text] [Related]
3. Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals.
Krix M; Kiessling F; Vosseler S; Kiessling I; Le-Huu M; Fusenig NE; Delorme S
Ultrasound Med Biol; 2003 Aug; 29(8):1093-103. PubMed ID: 12946512
[TBL] [Abstract][Full Text] [Related]
4. Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice.
Jugold M; Palmowski M; Huppert J; Woenne EC; Mueller MM; Semmler W; Kiessling F
Eur Radiol; 2008 Apr; 18(4):753-8. PubMed ID: 18084768
[TBL] [Abstract][Full Text] [Related]
5. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography.
Kiessling F; Krix M; Heilmann M; Vosseler S; Lichy M; Fink C; Farhan N; Kleinschmidt K; Schad L; Fusenig NE; Delorme S
Invest Radiol; 2003 Aug; 38(8):516-24. PubMed ID: 12874518
[TBL] [Abstract][Full Text] [Related]
6. Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies.
Cheung AM; Brown AS; Cucevic V; Roy M; Needles A; Yang V; Hicklin DJ; Kerbel RS; Foster FS
Ultrasound Med Biol; 2007 Aug; 33(8):1259-68. PubMed ID: 17467156
[TBL] [Abstract][Full Text] [Related]
7. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.
Vosseler S; Mirancea N; Bohlen P; Mueller MM; Fusenig NE
Cancer Res; 2005 Feb; 65(4):1294-305. PubMed ID: 15735015
[TBL] [Abstract][Full Text] [Related]
9. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
Franco M; Man S; Chen L; Emmenegger U; Shaked Y; Cheung AM; Brown AS; Hicklin DJ; Foster FS; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3639-48. PubMed ID: 16585189
[TBL] [Abstract][Full Text] [Related]
10. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
[TBL] [Abstract][Full Text] [Related]
11. Dynamic T1-weighted monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging.
Kiessling F; Heilmann M; Vosseler S; Lichy M; Krix M; Fink C; Kiessling I; Steinbauer H; Schad L; Fusenig NE; Delorme S
Int J Cancer; 2003 Mar; 104(1):113-20. PubMed ID: 12532427
[TBL] [Abstract][Full Text] [Related]
12. Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment.
Palmowski M; Huppert J; Hauff P; Reinhardt M; Schreiner K; Socher MA; Hallscheidt P; Kauffmann GW; Semmler W; Kiessling F
Cancer Res; 2008 Sep; 68(17):7042-9. PubMed ID: 18757418
[TBL] [Abstract][Full Text] [Related]
13. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
14. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants.
Miller DW; Vosseler S; Mirancea N; Hicklin DJ; Bohlen P; Völcker HE; Holz FG; Fusenig NE
Am J Pathol; 2005 Nov; 167(5):1389-403. PubMed ID: 16251423
[TBL] [Abstract][Full Text] [Related]
15. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
16. Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.
Lamuraglia M; Barrois G; Le Guillou-Buffello D; Santin M; Kerbol A; Comperat E; Coron A; Lucidarme O; Bridal SL
Technol Cancer Res Treat; 2020; 19():1533033819886896. PubMed ID: 32065066
[TBL] [Abstract][Full Text] [Related]
17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
18. A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion.
Krix M; Kiessling F; Farhan N; Schmidt K; Hoffend J; Delorme S
Ultrasound Med Biol; 2003 Oct; 29(10):1421-30. PubMed ID: 14597339
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
20. Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
Kozin SV; Winkler F; Garkavtsev I; Hicklin DJ; Jain RK; Boucher Y
Cancer Res; 2007 Jun; 67(11):5076-82. PubMed ID: 17545583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
